European Medicines Agency workshop on biosimilar monoclonal antibodies July 2, 2009, London, UK
FONTE
Landes Bioscience
RESUMO
The European Medicines Agency (EMEA) workshop on biosimilar monoclonal antibodies (mAbs), held July 2, 2009 at the EMEA headquarters in London, was a harbinger with potentially far-reaching implications for all groups interested in antibody therapeutics development. These groups include not only regulators and the innovator and generic biopharmaceutical industries, but also physicians, patients and payers. The objective of the workshop was to discuss and assess the feasibility of the development and authorization of mAbs using EMEA's biosimilar regulatory pathways. The workshop sequentially focused on questions relevant to three areas: (1) chemistry, manufacturing and controls (CMC), (2) non-clinical issues and (3) clinical issues, including outcome measures. Proceedings of the workshop are presented in Part 1 of this report, and discussed within the context of the legal, regulatory and business environments of the European Union, Asia and the United States in Parts 2, 3 and 4, respectively.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2759489Documentos Relacionados
- 5th Annual Monoclonal Antibodies Conference: March 24–25, 2009, London, UK
- The Royal Society Scientific Information Conference, London, June 21-July 2, 1948
- Sixth International Workshop on Scleroderma Research, Oxford, UK, 30 July–2 August 2000
- Cytokines in systemic lupus erythematosus, London, UK
- First International Congress on Medical Librarianship, London, July 20-26, 1953 *